Investigation of GREMLIN 1, COL15A1 immunoreactivity and the relationship between microvessel density and GREMLIN 1 in papillary renal cell carcinoma and chromophobe renal cell carcinoma
Article Sidebar
Main Article Content
Abstract
Objective: The current study aimed to investigate expressions of Gremlin 1 (GREM1) (a bone morphogenetic protein antagonist and a proangiogenic factor) and COL15A1 (Collagen type XV alpha-1, encodes the proteoglycans
located in various human tissues and particularly in the basement membrane) immunohistochemically in papillary renal cell carcinoma (PRCC) and chromophobe renal cell carcinoma (CRCC) in order to assess the relationship between these markers and said tumors and also explore associations of GREM1 with angiogenesis, tumor necrosis and tumor diameter by looking at the microvascular density (MVD) through the expression of COL15A1 in vascular endothelium.
Material and Method: GREM1 and COL15A1 expressions were investigated in 20 PRCC and 39 CRCC patients. Cytoplasmic staining with GREM1 and COL15A1 was examined. Microvascular structures stained with COL15A1 were examined in order to evaluate angiogenic profile.
Results: In CRCC, GREM1 staining was statistically significant in tumor tissues compared to intact tissues (p=0.006). The relationship between MVD and GREM1 staining was statistically significant in PRCC (p=0.007). Cytoplasmic staining with COL15A1 observed in PRCC was statistically significant (p=0.005).
Conclusion: Positive GREM1 staining observed in both tumor groups and much higher expression of this marker particularly in the tubular epithelium of the neighboring normal tissue supports our argument that this gene might be a tumor suppressor gene.
Downloads
Article Details
References
van Vlodrop IJ, Baldewijns MM, Smits KM, Schouten LJ, van Neste L, van Criekinge W, et al. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. The American journal of pathology. 2010;176(2):575–84.
Stabile H, Mitola S, Moroni E, Belleri M, Nicoli S, Coltrini D, et al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood. 2007;109(5):1834–40.
Amenta PS, Scivoletti NA, Newman MD, Sciancalepore JP, Li D, Myers JC. Proteoglycan-collagen XV in human tissues is seen linking banded collagen fibers subjacent to the basement membrane. Journal of Histochemistry & Cytochemistry. 2005;53(2):165–76
Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010; 29(14):2104-17.
Yıldız K. Böbrek tümörlerinin patolojik sınıflamasında güncel gelişmeler. Üro-onkoloji bülteni 2011;3:86-90.
Ellinger J, Holl D, Nuhn P, Kahl P, Haseke N, Staehler M, et al. DNA hypermethylation in papillary renal cell carcinoma. BJU international. 2011;107(4):664–9.
Chen M-H, Yeh Y-C, Shyr Y-M, Jan Y-H, Chao Y, Li C-P, et al. Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors. Journal of gastroenterology. 2013;48(1):101–8.
Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. 2010;127(12):2893–917.
Pascual D, Borque A. Epidemiology of kidney cancer. Advances in urology. 2008;782381.
Mills SE, Strenberg’s Diagnostic Surgıcal Pathology, fifth edition, Wolters Kluwer, Lippincott Williams anda Wilkins 2010;1757-98.
Bora G, Yurter H. Epigenetic diseases and therapeutic approaches. Hacettepe Tıp Dergisi. 2007; 38:48-54.
Mulvihill MS, Kwon Y-W, Lee S, Fang LT, Choi H, Ray R, et al. Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. PloS one. 2012;7(8):1-8
Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proceedings of the National Academy of Sciences. 2006;103(40):14842–7.
Wang D-J, Zhi X-Y, Zhang S-C, Jiang M, Liu P, Han X-P, et al. The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma. Oncology reports. 2012;27(1):58–64.
Namkoong H, Shin SM, Kim HK, Ha S-A, Cho GW, Hur SY, et al. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC cancer. 2006;6(1):74
Karagiannis GS, Musrap N, Saraon P, Treacy A, Schaeffer DF, Kirsch R, et al. Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression. Biol Chem. 2015;396(2):163–83.
Yan K, Wu Q, Yan DH, Lee CH, Rahim N, Tritschler I, et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev. 2014;28(10):1085–100.